AAV-mediated FOXG1 gene replacement for FOXG1 syndrome: dosage constraints and considerations for c.217C>T (p.Gln73Ter)

AAV-mediated FOXG1 gene replacement is being pursued as a potential therapeutic strategy for FOXG1 syndrome, driven by organizations including the FOXG1 Research Foundation. However, FOXG1 is critically dosage-sensitive: both haploinsufficiency and overexpression (as seen in FOXG1 duplication cases and 14q12 duplications) cause severe neurodevelopmental phenotypes. The c.217C>T (p.Gln73Ter) nonsense variant creates a premature stop at residue 73, upstream of the forkhead domain (FHD, residues ~181-275), producing a severely truncated, non-functional protein. This is a clear loss-of-function allele amenable to gene replacement, provided expression can be tightly controlled.

FOXG1 encodes a winged-helix transcription factor essential for telencephalic development, GABAergic interneuron specification, and postnatal neuronal survival. The forkhead domain (FHD) mediates DNA binding and is located at residues ~181-275 — the p.Gln73Ter truncation eliminates this entire domain along with downstream transcriptional regulatory regions. FOXG1 syndrome presents with severe microcephaly, absent speech, dyskinesia, and corpus callosum abnormalities, typically manifesting by 3-6 months of age. The FOXG1 Research Foundation has funded preclinical gene therapy programs, and AAV-FOXG1 vectors have been tested in Foxg1 heterozygous knockout mice. Intracerebroventricular (ICV) or intrathecal AAV9 delivery is the likely route given that FOXG1 is primarily expressed in the forebrain. Key preclinical work has demonstrated partial phenotypic rescue in mouse models, though the therapeutic window for a neurodevelopmental transcription factor remains a central question.

FOXG1 dosage sensitivity is the primary obstacle: FOXG1 duplications cause intellectual disability and epilepsy, meaning that even modest overexpression could be harmful. Unlike structural proteins where excess may be tolerated, transcription factor dosage must be precisely controlled — a challenge no current AAV regulatory element has fully solved. Developmental timing is critical: FOXG1 functions primarily during embryonic forebrain patterning, and postnatal gene replacement may only address FOXG1 roles in neuronal maintenance rather than restoring mis-patterned circuits. BBB penetration and widespread forebrain transduction are technically demanding. No clinical trial for FOXG1 gene therapy has been registered as of the knowledge cutoff. The mouse model (Foxg1+/-) does not fully recapitulate human FOXG1 syndrome severity. The c.217C>T variant specifically has not been studied in any preclinical gene therapy experiment.